doi:10.1007/s12603-010-0330-4
A quinolinium-based, selective NNMT inhibitor used to interrogate NNMT biology in cells and animal models of obesity, insulin resistance, and related metabolic phenotypes (commonly as the iodide salt
The peptide did not produce adverse metabolic effects associated with full-length growth hormone, including insulin resistance, glucose intolerance, or IGF-1 elevation
Many patients report a crisp surge in mental alertness, clarity, and physical stamina within 12 to 24 hours post-injection
Clinical research demonstrated that AOD-9604 does not elevate IGF-1 levels, which distinguishes it from other fat loss peptides
For patients with these conditions, a maintenance schedule of injections every one to three months is typical after getting their levels back up